• Tumor-induced immune suppression of the host may pose a barrier to successful immunotherapy. A monoclonal antibody (MAb 14-12) able to bind and inhibit murine soluble T-cell suppressor factor was tested for in vivo antitumor activity by treatment of mice bearing three-day established pulmonary metastases of a weakly immunogenic methylcholanthreneinduced fibrosarcoma (MCA 106). Administration intraperitoneally in combination with interleukin 2 (IL-2), a growth factor for activated T lymphocytes, resulted in a significant reduction (60% to 90%) of metastases. Neither IL-2 nor monoclonal antibody alone had significant antitumor effects. This study demonstrates in vivo potentiation of IL-2 antitumor activity with an anti—T-cell suppressor factor and points to possible strategies for clinical application.
(Arch Surg 1987;122:1455-1459)
Kim B, Warnaka P, Iverson M, Imbembo AL. Immunotherapy of Pulmonary Metastases Using Monoclonal Antibody to T-Cell Suppressor Factor and Interleukin 2. Arch Surg. 1987;122(12):1455-1459. doi:10.1001/archsurg.1987.01400240103019